{"denoms":[{"counts":[{"groupId":"BG000","value":"265"},{"groupId":"BG001","value":"265"},{"groupId":"BG002","value":"530"}],"units":"Participants"}],"groups":[{"description":"Participants were randomized to sabatolimab plus Azacitidine","id":"BG000","title":"Sabatolimab (MBG453) + Azacitidine"},{"description":"Participants were randomized to placebo plus Azacitidine","id":"BG001","title":"Placebo + Azacitidine"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.46","value":"70.2"},{"groupId":"BG001","spread":"11.23","value":"69.1"},{"groupId":"BG002","spread":"11.35","value":"69.6"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"104"},{"groupId":"BG001","value":"79"},{"groupId":"BG002","value":"183"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"161"},{"groupId":"BG001","value":"186"},{"groupId":"BG002","value":"347"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"150"},{"groupId":"BG001","value":"134"},{"groupId":"BG002","value":"284"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"111"},{"groupId":"BG001","value":"124"},{"groupId":"BG002","value":"235"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"7"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"Unknown"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"92"},{"groupId":"BG001","value":"101"},{"groupId":"BG002","value":"193"}]}],"title":"ECOG performance status: 0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"161"},{"groupId":"BG001","value":"141"},{"groupId":"BG002","value":"302"}]}],"title":"ECOG performance status: 1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"35"}]}],"title":"ECOG performance status: 2"}],"description":"Eastern Cooperative Oncology Group (ECOG) performance status scale is a widely used standard of care criteria used to assess the functional status of a patient with cancer to measure how the disease impacts the patient's daily living abilities. This scale has a range from 0 - 5. The higher the grade, the worse the patient's abilities: 0 implies fully active, able to carry on all pre-disease performance without restriction and 5 implies death.","paramType":"COUNT_OF_PARTICIPANTS","title":"ECOG performance status","unitOfMeasure":"Participants"}],"populationDescription":"The Full Analysis Set (FAS) comprised of all participants to whom study treatment had been assigned by randomization."}